INVA logo

INNOVIVA INC

INVANASDAQ
🏆 #2171 by market capUS Equity
$385.43▼ $25.79 (−6.69%)
Simulated price
🔔
Track INVA
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 6.7%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$1.57B
Small Cap
📈Revenue Growth (YoY)
+18.5%
Healthy
📊Gross Margin
73.1%
High
💵FCF Margin
42.5%
Strong
⚖️P/S Ratio
3.5x
Fair
Otter Score
60
Fair
No chart data available for INVA.

Trading Snapshot

Day Range
$380.58 – $389.31
52-Week Range
$16.52 – $25.15
Volume
$2.01B
Avg Volume
$1.80B
Shares Outstanding
73.8M
Next Earnings
Nov 28, 2026

Fundamentals Snapshot

Annual Revenue
$425M
Last Q Revenue
$120M
P/E Ratio
4.4
P/S Ratio
3.5x
EPS (TTM)
$4.87
Dividend Yield
0.00%
Dilution (1yr)
+1.3%

Why Investors Own INVA

  • ✓High-growth profile — revenue up +7.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 79% gross margin and 9% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

INVA logo

INNOVIVA INC

INVA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$425M▲ +18.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
72.3%▼ −19.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$164M▼ −1.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$186M▼ −1.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
85.3M▲ +1.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$282M▲ +$428M YoY
StockOtter · stockotter.space

About INNOVIVA INC

Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$379.78
▼ −1.5% Downside
High Target$441.43
Low Target$314.95
Based on 33 analysts

Latest News & Updates

🚀
Barron’s·2h ago

INNOVIVA INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift INVA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

INNOVIVA INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.